The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer (RADIT).
Martin H Fenner
Research Funding - Novartis
Annette Dieing
No relevant relationships to disclose
Karin Oechsle
No relevant relationships to disclose
Marcus Hentrich
No relevant relationships to disclose
Thomas Christoph Gauler
No relevant relationships to disclose
Anja Lorch
No relevant relationships to disclose
Hans-Georg Kopp
No relevant relationships to disclose
Joerg Beyer
No relevant relationships to disclose
Carsten Bokemeyer
No relevant relationships to disclose
Viktor Gruenwald
Honoraria - Novartis
Research Funding - Novartis
Friedemann Honecker
No relevant relationships to disclose